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Abstract
Haloperidol is an antipsychotic drug that exerts its’ antipsychotic effects by inhibiting dopaminergic neurons.
Although the exact pathophysiology of haloperidol extrapyramidal symptoms are not known, the role of reactive
oxygen species in inducing oxidative stress has been proposed as one of the mechanisms of prolonged
haloperidol-induced neurotoxicity. In the present study, we evaluate the protective effect of alpha lipoic acid
against haloperidol-induced oxidative stress in the rat brain. Sprague Dawley rats were divided into control, alpha
lipoic acid alone (100 mg/kg p.o for 21 days), haloperidol alone (2 mg/kg i.p for 21 days), and haloperidol with
alpha lipoic acid groups (for 21 days). Haloperidol treatment significantly decreased levels of the brain antioxidant
enzymes super oxide dismutase and glutathione peroxidase and concurrent treatment with alpha lipoic acid
significantly reversed the oxidative effects of haloperidol. Histopathological changes revealed significant
haloperidol-induced damage in the cerebral cortex, internal capsule, and substantia nigra. Alpha lipoic acid
significantly reduced this damage and there were very little neuronal atrophy. Areas of angiogenesis were also
seen in the alpha lipoic acid-treated group. In conclusion, the study proves that alpha lipoic acid treatment
significantly reduces haloperidol-induced neuronal damage.
Background
Haloperidol (HP) is a first generation antipsychotic fre-
quently used in the treatment of schizophrenia. It is a
drug of the butyrophenone class of neuroleptics [1] and
is thought to exert its antipsychotic effects by blocking
dopamine, especially through D2 receptor inhibition [2].
HP has strong activity against delusions and hallucina-
tions due to its effects on the mesolimbic pathway of
the brain. Its action on the nigrostriatal pathway, on the
other hand, is responsible for the side effects. The effect
of long-term administration of HP on the activity of
dopaminergic neurons is termed ‘depolarization block-
ade’; the chronic effect of HP is an inactivation of dopa-
mine neurons of the mesolimbic and nigrostriatal
pathways [3]. Researchers have postulated that the
‘depolarization block’ of the mesolimbic pathway is
responsible for the therapeutic efficacy of HP while the
decreased activity of the substantia nigra gives rise to
the extra-pyramidal side effects [4].
Usage of haloperidol is limited by the drug’s tendency
to exhibit a range of extra-pyramidal symptoms such as
Parkinsonism and tardive dyskinesia [5]. Tardive dyski-
nesia is a serious neurological syndrome associated with
the chronic use of neuroleptics. Such patients present
with symptoms such as involuntary lip smacking, suck-
ing or chewing, facial grimacing, or choreoathetoid-like
movements of limbs [6]. Tardive dyskinesia may persist
for months or years despite withdrawal and may be
irreversible.
The exact pathophysiology of haloperidol-induced
extra-pyramidal symptoms has yet to be elucidated. Oxi-
dative stress resulting from increased production of
reactive oxygen species (ROS) and a decrease in antioxi-
dant defense mechanisms is proposed as a pathogenic
mechanism. Treatment with HP causes dopaminergic
receptor blockade resulting in increased dopamine turn-
over rate. This can lead to generation of reactive oxygen
species as byproducts of its metabolism [7]. Apart from
the production of free radicals, HP administration is
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the antioxidant glutathione. Previous research has also
shown that coadministration of haloperidol and antioxi-
dants such as vitamin E resulted in beneficial effect in
patients with tardive dyskinesia [8].
Superoxide dismutase (SOD) and glutathione peroxi-
dase (GPx) are important antioxidant enzymes in the
body. SOD catalyses the conversion of superoxide free
radical to hydrogen peroxide and water [9]. GPx con-
tinues where SOD leaves off by catalyzing the reduction
of hydrogen peroxide to water at the expense of glu-
tathione [10]. Previous studies have shown that HP
reduces the activity of SOD and GPx [11] rendering the
body more vulnerable to oxidative damage.
Alpha lipoic acid (ALA) is a naturally occurring com-
pound synthesized in small quantities by most plants
and animals. In humans, ALA is synthesized in the
mitochondria from octanoic acid [12]. ALA functions as
an important cofactor for several important enzymes. It
has been shown recently that ALA also has a role in the
oxidative decarboxylation of pyruvate to acetyl CoA, the
step that bridges glycolysis and the Krebs cycle [13].
ALA can be found in dietary sources such as animal
liver, spinach, broccoli, and tomatoes [14,15].
Huge interest has been garnered in recent times on
the antioxidant properties of ALA and its reduced form
dihydrolipoic acid (DHLA). Both ALA and DHLA are
able to cross the blood-brain barrier and act as a redox
couple with very low reduction potentials [13]. Due to
these properties ALA is capable of regenerating other
important antioxidants such as glutathione, vitamin C,
and vitamin E [16,17]. It also has specificity for free
radical quenching and metal chelating apart from regen-
eration of other cellular antioxidants. Furthermore, due
to its action in both the membranous and aqueous
phase, ALA is frequently referred to as a universal
antioxidant.
Results and Discussion
Figure 1A and 1B show the mean activities of SOD and
figure 1C and 1D show the mean activities of GPx in
the serum and brain respectively. The results were com-
pared statistically and the mean activity of SOD and
GPx was significantly higher (p < 0.01) in the ALA
group than in the control group. On the other hand, the
mean activity of SOD and GPx was significantly lower
(p < 0.01) in the HP group than in the control group.
Comparing group 3 and group 4, it was noticed that the
rats that were co-administered HP and ALA showed a
significantly higher (p < 0.01) increase in SOD and GPx
activity in serum and brain compared to the rats that
were given HP alone.
The histological study of the contol brains showed
normal cellularity of the cerebral cortex and the basal
ganglia. Healthy neurons were seen with prominent
axons and dendrites (Figures. 2A and 3A). The histo-
pathological findings in the ALA-treated group were
similar to those in the control group (Figure 2B)
The group treated with HP showed changes that sug-
gested morphological damage (Figures. 2C and 3B).
Necrosis occurred in the cerebral cortex, internal cap-
sule, and substantia nigra. Layers of the cerebral cortex
were obliterated and replaced with zones of fibromyxoid
stroma. Fibrosis was also extensive in the internal cap-
sule and substantia nigra. When examined with higher
magnification, neurons were found to be atrophic and
there was loss of prominent axons and dendrites. In the
group treated with both ALA and HP, a small amount
of necrosis occurred in the substantia nigra but the
intensity of damage was minimal compared to the group
treated with HP alone. In most rats, the cerebral cortex
and internal capsule were spared. Areas of angiogenesis
were also noted, with sprouting of numerous capillaries
and arterioles within areas of necrosis. Atrophic neurons
were infrequent and the majority of neurons were
healthy with visible axons and dendrites (Figures. 2D
and 3C).
Rats treated with HP showed a significant decrease
in mean SOD and GPx activity. These results sup-
ported the hypothesis that HP induces oxidative stress.
SOD catalyzes the dismutation of superoxide radicals
to form hydrogen peroxide, which in turn is decom-
posed to water and oxygen by GPx. These enzymes
work together to protect the body from free radicals.
The reduced activity of SOD and GPx in rats treated
with HP increases the vulnerability to the effects of
free radicals. Oxidative stress is compounded by the
generation of free radicals due to the action of HP. HP
blockade of dopamine receptors increases dopamine
turnover, which in turn leads to the increased produc-
tion of hydrogen peroxide. The decrease in enzymatic
activities of SOD and GPx is possibly due to HP
decreasing the genetic expression of these enzymes
[18]. On the other hand, the activity of these enzymes
was brought back to normal levels with co-administra-
tion of ALA. This result probably can be explained by
the effect of ALA on nerve growth factor (NGF). NGF
p r o v i d e st h ee x p r e s s i o no fS O Dg e n ea n dt h e r ei sa
possibility that ALA enhances NGF-induced regulation
of SOD gene. This could be a factor leading to an
increase in SOD activity [19]; GPx activity too was also
restored to a normal level by the co-administration of
ALA. GPx catalyzes the reduction of hydrogen perox-
ide to water and oxygen at the expense of glutathione
(GSH). Therefore the increase in GPx activity indicates
that more oxidized glutathione (GSSH) is reduced to
GSH. This recycling of glutathione is hypothesized to
be due to ALA.
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pathological and biochemical analyses in our study is
striking. The increased vulnerability of the rat brain to
oxidative stress as shown by decreased antioxidant
enzymes was mirrored in histopathological findings.
Degenerative changes were apparent in the striatum,
substantia nigra, and internal capsule in rats treated
with HP. The resulting photomicrographs revealed mas-
sive areas of necrosis, fibrosis, and atrophic neurons.
These findings are in accordance with previous studies
that showed nigral pathology upon HP administration
[20,21]. Pathological changes also strengthen the free
radical hypothesis of HP. The inhibitory action of HP
on D2 receptors causes an increased turnover in dopa-
mine which then leads to the formation of hydrogen
peroxide and other free radicals. The increase in free
radical formation, coupled with decreased SOD and
GPx enzyme activity in the brain as established in our
study is possibly the basis for oxidative damage to the
brain. The degenerative changes were not confined to
the basal ganglia and internal capsule but affected the
cerebral cortex as well indicating the extent of the HP-
induced oxidative damage.
When ALA was co-administered with HP, the cerebral
cortex and internal capsule were spared of degenerative
changes. There was normal cellular morphology and
each layer of the cerebral cortex was intact but necrosis
and atrophic neurons still were found in the basal gang-
lia. Nevertheless, necrotic and atrophic changes were
smaller when ALA was co-administered with HP than
when HP was administered alone. Thus, ALA may have
played a protective role in HP-induced oxidative damage
in the brain. The sprouting of numerous capillaries that
was seen in necrotic areas of the brain signifying
Figure 1 Superoxide dismutase (SOD) and Glutathione peroxidase levels in serum and brain. A - Serum SOD {Mean SOD Activity (U/ml)}
B - Brain SOD {Mean SOD activity (U/ml)} C - Serum GPx {Mean GPx activity (nmol/min/ml)}D - Brain GPx {Mean GPx activity (nmol/min/ml)},
Values are Mean ± SEM, p < 0.05.
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brain from oxidative damage and facilitates healing.
The neuroprotective effects of ALA demonstrated in
this study can be explained by its antioxidant properties.
ALA is reduced to DHLA in the cells, forming a redox
couple. ALA and DHLA prevent oxidative damage by
interacting with ROS. ALA and DHLA are able to sca-
venge free radicals such as singlet oxygen and hydroxyl
radicals. They also chelate metal ions which are involved
in ROS formation. In the event that SOD and GPx
activities were affected when the rats were treated with
HP, ALA probably compensates for SOD and GPx
action. Moreover, ALA is also known to regenerate
other antioxidants such as glutathione, vitamin E, vita-
min C, and coenzyme Q10. The newly reduced glu-
tathione, vitamin C, and coenzyme Q also regenerate
oxidized vitamin E, forming an antioxidant network that
protects the body from HP-induced oxidative damage.
The present study showed that HP causes oxidative
stress. This conclusion was based on the findings that
administration of HP significantly decreased SOD and
GPx activity in rat brain and serum. Histopathological
studies showed the deleterious effect of HP on the rat
brain as massive necrosis, fibrosis, and atrophic neurons.
The histopathological changes correlated with the bio-
chemical assay results.
We found that rats treated with ALA showed a much
greater increase in body weight. In addition, rats treated
with ALA also showed a significant increase in brain ACh
concentration. Our other objective was to investigate the
effects of ALA on HP-induced alterations towards the
antioxidant defense system in the rat brain. The adminis-
tration of ALA to HP-treated rats, restored the activity of
SOD and GPx in both serum and brain and demonstrated
a distinct protective effect in histopathological studies.
The significant increase in antioxidant activity coupled
with the histological evidence, leads to the conclusion that
ALA reduces HP-induced oxidative damage in rat brain.
Methods
A total of 32 male Sprague-Dawley rats (180-250 g body
weight) were used in this study. The rats were housed
Figure 2 Photomicrograph of neurons (400×, H&E stain). A - Photomicrograph of A - control group depicting normal neurons and axons. B
- ALA group showing normal parenchymal tissue with good cellular morphology and surrounding glial tissue, C - HP group showing atrophic
nerve fibers and loss of prominent axons, D - ALA+HP group showing normal and healthy neurons (400×, H&E stain).
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± 3°C, humidity 40-60%) with 12 hour light and dark
cycles. Food and water were supplied ad libitum prior
to the start of the experiment. All the experiments were
carried out according to the standard guidelines for ani-
mal experiments and Institutional Ethics Committee has
approved this research project.
Each drug used in this experiment was purchased in
the powder form (Sigma Aldrich Co. USA); conse-
quently, each drug was dissolved before administration
to rats. Rats were weighed daily. Drug solutions were
given at 1 ml/200 g body weight. ALA solution was
given oral gavage using a stainless steel oral feeding
tube. Intraperitoneal injections of HP were administered
using a 1.0 mL syringe with a 21 gauge needle to pre-
vent damage to the internal organs of rats.
On the 22
nd day of the experiment, the rats were
anaesthetized with ether. A blood sample was collected
by cardiac puncture. Blood was transferred into 5 ml
tubes, which were centrifuged using Sigma 2-16 KC
Refrigerated Centrifuge at 3000 rpm for 10 minutes at
4°C. The serum was extracted using a 1 ml syringe and
stored at -20°C until further analysis.
Brain was dissected out and photographed using a
digital camera, for gross inspection. Brain was sectioned
into two halves. One half of the brain was kept in 50 ml
tube filled with 10% formalin for a month before proces-
sing for histopathological studies. The other half of the
brain was transferred into 15 ml Falcon tubes filled with
phosphate buffer solution and stored at -20°C. Brain
samples were thawed and homogenized in ice to ensure
the viability of proteins using a Duall, all-glass, tissue
grinder. The homogenate was centrifuged using Sigma
2-16 KC Refrigerated Centrifuge at 6000 rpm for 20
minutes at 4°C. The samples were maintained at -20°C
before performing biochemical assays. From the brain
homogenate samples, superoxide dismutase (SOD) and
glutathione peroxidase (GPx) were assayed using ELISA
Figure 3 Photomicrograph of neurons with visible axons (1000×, H&E stain). Photomicrograph of A - control group showing normal
neurons with visible axons. B - HP group showing atrophic nuclei at a higher magnification with loss of prominent axons and dendrites. C -
Photomicrograph of ALA+HP group showing formation of numerous capillaries (1000×, H&E stain).
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USA).
Super oxide dismutase assay kit utilizes a tetrazolium
salt for the detection of superoxide radicals (O2-) gener-
ated by xanthine oxidase and hypoxanthine. One unit of
SOD is defined as the amount of enzyme necessary to
exhibit 50% dismutation of the superoxide radical. Oxi-
dation rate of tetrazolium salt to formazan dye by O2 -
is inversely proportional to the endogenous activity of
SOD. The formazan dye stains the wells and its staining
intensity was detected by absorbance spectrophotometry
at 450 nm using a plate reader. Superoxide dismutase
levels were determined from a standard curve and
expressed as U/mg of protein [22,23].
Glutathione peroxidase assay kit measures GPx levels
indirectly by a coupled reaction with glutathione reduc-
tase. Oxidized glutathione, produced upon reduction of
an organic hydroperoxide by GPx, is recycled to its
reduced state by glutathione reductase and NADPH.
The oxidation of NADPH to NADP+ is accompanied by
a decrease in absorbance at 340 nm. The rate of
decrease in the absorbance at 340 was directly propor-
tional to the GPx levels in the sample. Glutathione per-
oxidase enzyme levels were expressed as nmol/mg of
protein [22,24].
Statistical analysis was done using Statistical Package
for Social Sciences (SPSS) version 15.0. Data obtained
were expressed as mean ± standard deviation (SD). Ana-
lysis of variance (ANOVA) followed by multiple range
test was used to determine significant differences. Dif-
ferences at p < 0.05 were considered to be statistically
significant.
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